MMJ BioPharma’s noble pursuit of scientific advancement has been met with a series of inexplicable roadblocks and bureaucratic hurdles erected by the DEA. In 2018, the company dutifully applied for the necessary licenses to cultivate marijuana for research and development purposes, eagerly anticipating the opportunity to commence clinical trials that could yield life-changing treatments. Yet, despite meticulously following the DEA’s convoluted application process, MMJ BioPharma found itself trapped in a seemingly endless cycle of delays, obfuscation, and stonewalling.
The cannabis industry presents an array of high-paying job opportunities across various sectors—from finance and…
Recent studies have indicated a notable decrease in prescriptions for anti-anxiety medications, especially benzodiazepines, in…
We’ve assembled a list of fantastic brands and products from around the cannabis universe to…
If there's one thing I've learned from years of covering cannabis politics, it's that weed…
As we wrap up our deep dive into cannabis and exercise, I can't help but…
With Zoap, Cadillac Rainbow, and Blueberry Caviar. The post Leafly Buzz: 12 hot strains to…